次新股丸美股份(603983.SH)一度跳水跌超8% 上市4個月較IPO價漲230%
格隆匯11月21日丨次新股丸美股份(603983.SH)盤中出現一波跳水走勢,一度大跌超8%,現報67.7元,跌6.34%,暫成交3億元,最新總市值271億元,最新估值在50倍左右。

公司為一家護膚品企業,主要從事各類化粧品的研發、設計、生產、銷售及服務。今年7月上市,IPO價格為20.54元,一度在11月4日創上市最高價75.57元,相較於IPO價格最高累計漲幅一度達268%,現價較IPO價累計漲幅達高達229.6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.